UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 24, 2018
KURA ONCOLOGY, INC.
(Exact name of Registrant as Specified in Its Charter)
| | | | |
| Delaware | | 001-37620 | | 61-1547851 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| |
| 3033 Science Park Road, Suite 220, San Diego, CA | | 92121 |
| (Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (858)500-8800
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule12b-2 of the Securities Exchange Act of 1934(§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01 Other Events
On January 24, 2018, Kura Oncology, Inc. (the “Company”) sold 3,136,722 shares of its common stock during intraday trading at a weighted average price per share of $18.85 for gross proceeds of approximately $59.1 million. The shares were sold pursuant to the Company’s sales agreement with Cowen and Company, LLC (“Cowen”) dated January 27, 2017, as amended on November 9, 2017. Following these sales, the Company may offer and sell additional shares of its common stock having an aggregate offering price of up to $40.7 million from time to time through Cowen pursuant to the sales agreement.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | | | |
| | | | KURA ONCOLOGY, INC. |
| | | |
| Date: January 24, 2018 | | | | By: | | /s/ Annette North |
| | | | | | Annette North |
| | | | | | Senior Vice President and General Counsel |
